{"analyses":[{"ciLowerLimit":"4.0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"25.3","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0077","pValueComment":"Model included treatment+visit+treatment by visit interaction+stratification factor for region (U.S. versus non-U.S.)+joint type (knee, ankle, or other)+the most impaired ROM baseline value.","paramType":"LS Mean Difference","paramValue":"14.6","statisticalMethod":"Mixed model repeated measures"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.46","value":"18.4"},{"groupId":"OG001","spread":"7.19","value":"3.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"Presented here is the change from baseline in active ROM to Week 25. Measurement of the affected and contralateral, non-affected joint was assessed by goniometer and measured in degrees. At baseline, the motion with the smallest relative ROM value (worst) was identified, and this motion was used for evaluating the change in relative ROM subsequently. The affected joint measurement was used to derive a relative ROM based on active measurement relative to reference standard value provided by the American Medical Association. Relative ROM is expressed in percent: 100 x (joint ROM measure)/(reference ROM standard).","dispersionType":"Standard Error","groups":[{"description":"Participants received 30 mg BIW vimseltinib for 24 weeks.","id":"OG000","title":"Vimseltinib"},{"description":"Participants received matching placebo BIW for 24 weeks.","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The ITT Set consisted of participants who were randomized to a study treatment regimen. Here, \"Overall Number of Participants Analyzed\" is the number of participants evaluable for this outcome measure at the specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 25 (Cycle 7, Day 1)","title":"Change From Baseline in Active Range of Motion (ROM) at Week 25","type":"SECONDARY","unitOfMeasure":"Change in percent"}